Trial · NCT00985725
Outcomes15
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 15 of 15
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change From Baseline in Behavior Rating Inventory of Executive Function - Adult Version Global Executive Composite T-score (BRIEF-A GEC T) at Week 9, Last Observation Carried Forward (LOCF) | Baseline and week 9 | The Full Analysis Set (FAS) defined as all randomized subjects who took at least 1 dose of randomized investigational product and had at least 1 primary efficacy assessment after baseline. | T-scores | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 9 - (LOCF) | Baseline and week 9 | FAS | Scores on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in BRIEF-A T-scores at Week 9, LOCF | Baseline and week 9 | FAS | T-scores | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Central Nervous System Vital Signs Computerized Cognitive Testing Battery Neurocognitive Domain and Index Scores at up to 9 Weeks/Endpoint | Baseline and up to 9 weeks/Endpoint | FAS | Response scores | MEAN |
| SECONDARY | Percent of Participants With Clinical Global Impression - Severity of Illness (CGI-S) at Baseline | Baseline | FAS | percentage of participants | NUMBER |
| SECONDARY | Percent of Participants With CGI-S at up to 9 Weeks/Endpoint | Up to 9 weeks/Endpoint | FAS population was used for this assessment. However, not all subjects from the FAS completed this assessment, therefore the total number of subjects analyzed for this outcome is less than the total number of subjects that comprise the FAS population. | percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants With Improvement on Clinical Global Impression-Improvement (CGI-I) at Week 9, LOCF | Week 9 | FAS | percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in Endicott Work Productivity Scale (EWPS) Total Score at up to 9 Weeks/Endpoint | Baseline and up to 9 weeks/Endpoint | FAS population was used for this assessment. However, not all subjects from the FAS completed this assessment, therefore the total number of subjects analyzed for this outcome is less than the total number of subjects that comprise the FAS population. | Scores on a scale | LEAST_SQUARES_MEAN |
| SECONDARY | Change From Baseline in Changes in Sexual Functioning Questionnaire (CSFQ-14) Total Scores for Males at Week 9, LOCF | Baseline and week 9 | The Safety Analysis Set (SAS) defined as all randomized subjects who took at least 1 dose of investigational product and for whom at least 1 follow-up safety assessment was completed. Only the males from the SAS population were used and not all of them completed this outcome assessment. | Scores on a scale | MEAN |
| SECONDARY | Change From Baseline in CSFQ-14 Total Scores for Females at Week 9, LOCF | Baseline and week 9 | Only the females from the SAS population were used and not all of them completed this outcome assessment. | Scores on a scale | MEAN |
| SECONDARY | Change From Baseline in Short Form-12 Health Survey (SF-12) Scale Total Scores at Week 9 | Baseline and week 9 | FAS population was used for this assessment. However, not all subjects from the FAS completed this assessment, therefore the total number of subjects analyzed for this outcome is less than the total number of subjects that comprise the FAS population. | Scores on a scale | MEAN |
| SECONDARY | Change From Baseline in Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Total Scores at up to 9 Weeks/Endpoint | Baseline and up to 9 weeks/Endpoint | FAS population was used for this assessment. However, not all subjects from the FAS completed this assessment, therefore the total number of subjects analyzed for this outcome is less than the total number of subjects that comprise the FAS population. | Scores on a scale | MEAN |
| SECONDARY | Change From Baseline in Amphetamine Cessation Symptom Assessment (ACSA) Total Score at Week 11 | Baseline and week 11 | SAS population was used for this assessment. However, not all subjects from the SAS completed this assessment, therefore the total number of subjects analyzed for this outcome is less than the total number of subjects that comprise the SAS population. | Scores on a scale | MEAN |
| SECONDARY | Change From Baseline in the Generalized Anxiety Disorder 7-Item (GAD-7) Total Score at Week 9, LOCF | Baseline and week 9 | SAS | Scores on a scale | MEAN |
| SECONDARY | Change From Baseline in Sheehan Suicidality Tracking Scale (STS) Total Score at Week 9 | Baseline and week 9 | SAS population was used for this assessment. However, not all subjects from the SAS completed this assessment, therefore the total number of subjects analyzed for this outcome is less than the total number of subjects that comprise the SAS population. | Scores on a scale | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00985725/outcomes